Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Saved in:
| Title: | Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. |
|---|---|
| Authors: | Bolton AE; Novartis Pharma AG, Basel, Switzerland. ann.bolton@pharma.novartis.com, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2004 Feb; Vol. 53 (2), pp. 102-6. Date of Electronic Publication: 2003 Nov 07. |
| Publication Type: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0344-5704 (Print) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
